UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA)

Osteoarthritis and cartilage, 2018-01, Vol.26 (1), p.34-42

2018

Volltextzugriff (PDF)

Sustained efficacy of a single intra-articular dose of FX006 in a rat model of repeated localized knee arthritis

Osteoarthritis and cartilage, 2015-01, Vol.23 (1), p.151-160

2015

Volltextzugriff (PDF)

An intra-articular, extended release formulation of triamcinolone (FX006) affords clinically relevant improvements in pain and function of knee osteoarthritis: post-hoc pooled analyses of 3 randomized controlled trials

Osteoarthritis and cartilage, 2017-04, Vol.25, p.S432-S433

2017

Volltextzugriff (PDF)

Systemic and local effects following intra-articular injection of FX006, an extended release, PLGA microsphere formulation of triamcinolone acetonide: results from two nonclinical toxicity studies in dogs

Osteoarthritis and cartilage, 2017-04, Vol.25, p.S431-S432

2017

Volltextzugriff (PDF)

Synovial and systemic pharmacokinetics of triamcinolone acetonide following intra-articular injection of an extended release formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis

Osteoarthritis and cartilage, 2017-04, Vol.25, p.S431-S431

2017

Volltextzugriff (PDF)

A single intra-articular dose of Fx006, an extended-release formulation of triamcinolone acetonide, has a similar effect on cartilage in healthy dogs as the commonly used kenalog-40® suspension

Osteoarthritis and cartilage, 2014-04, Vol.22, p.S463-S464

2014

Volltextzugriff (PDF)

Sustained and profound analgesic benefits in people with osteoarthritis of the knee using FX006, an intra-articular extended-release formulation of triamcinolone acetonide: Results from a double-blind, randomized, parallel-group, dose-ranging study

Osteoarthritis and cartilage, 2016-04, Vol.24, p.S49-S50

2016

Volltextzugriff (PDF)

Sustained efficacy of intra-articular FX006 in a rat model of osteoarthritis

Osteoarthritis and cartilage, 2012-04, Vol.20, p.S289-S289

2012

Volltextzugriff (PDF)

Prolonged joint residency of triamcinolone acetonide after an intra-articular injection of FX006, a sustained release formulation for the treatment of osteoarthritis

Osteoarthritis and cartilage, 2015-04, Vol.23, p.A360-A361

2015

Volltextzugriff (PDF)

FX006 prolongs the residency of triamcinolone acetonide in the synovial tissues of patients with knee osteoarthritis

Osteoarthritis and cartilage, 2013-04, Vol.21, p.S144-S145

2013

Volltextzugriff (PDF)

Safety and efficacy of FX006 in patients with osteoarthritis of the knee

Osteoarthritis and cartilage, 2014-04, Vol.22, p.S376-S377

2014

Volltextzugriff (PDF)

A novel structural status assessment of oa is strongly associated with all patient important outcomes - an mri study of 9,433 knees from the osteoarthritis initiative

Osteoarthritis and cartilage, 2020-04, Vol.28, p.S47-S48

2020

Volltextzugriff (PDF)

The rat homolog to FX201, a gene therapy in development for the treatment of osteoarthritis, demonstrates dose-dependent decreases in the severity of cartilage and bone lesions following anterior cruciate ligament transection

Osteoarthritis and cartilage, 2020-04, Vol.28, p.S193-S194

2020

Volltextzugriff (PDF)

Dose-dependent chondroprotective effects of triamcinolone acetonide on inflamed and injured cartilage using an in vitro model

Osteoarthritis and cartilage, 2019-04, Vol.27, p.S176-S176

2019

Volltextzugriff (PDF)

The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease

Alzheimer disease and associated disorders, 1997, Vol.11, p.S16-S22

1997

Volltextzugriff (PDF)

(262) - Assay sensitivity of average daily pain (ADP) and western ontario and mcmaster osteoarthritis index A-pain (WOMAC-A) in a phase 3 trial of intra-articular FX006 for osteoarthritis knee pain

The journal of pain, 2018-03, Vol.19 (3), p.S76-S76

2018

Volltextzugriff (PDF)

Efficacy of xanomeline in Alzheimer disease : Cognitive improvement measured using the computerized neuropsychological test battery (CNTB)

Alzheimer disease and associated disorders, 1998-12, Vol.12 (4), p.304-312

1998

Volltextzugriff (PDF)

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

Archives of neurology (Chicago), 1997-04, Vol.54 (4), p.465-473

1997

Volltextzugriff (PDF)

Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines

Alzheimer disease and associated disorders, 1997, Vol.11 Suppl 3, p.6-7

1997

Volltextzugriff (PDF)

Growing Optic Nerve Fibers Follow Neighbors during Embryogenesis

Proceedings of the National Academy of Sciences - PNAS, 1980-07, Vol.77 (7), p.4374-4378

1980

Volltextzugriff (PDF)

Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist

The American journal of psychiatry, 1997-10, Vol.154 (10), p.1459-1461

1997

Volltextzugriff (PDF)

557 The MI-selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of patients with mild to moderate Alzheimer's disease

Neurobiology of aging, 1996, Vol.17 (4), p.S138-S139

1996

Volltextzugriff (PDF)

The M1 muscarinic agonist xanomeline improves both cognitive and behavioral deficits in Alzheimer's disease

European neuropsychopharmacology, 1996-06, Vol.6, p.144-144

1996

Volltextzugriff (PDF)

Quality-of-life assessment in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines

Alzheimer disease and associated disorders, 1997, Vol.11 Suppl 3, p.56-60

1997

Volltextzugriff (PDF)

Effects of Central Muscarinic-1 Receptor Stimulation on Blood Pressure Regulation

Hypertension (Dallas, Tex. 1979), 1997-03, Vol.29 (3), p.828-834

1997

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(41)
Tagungsberichte
(2)

Sprache

Englisch
(43)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA)

Sustained efficacy of a single intra-articular dose of FX006 in a rat model of repeated localized knee arthritis

An intra-articular, extended release formulation of triamcinolone (FX006) affords clinically relevant improvements in pain and function of knee osteoarthritis: post-hoc pooled analyses of 3 randomized controlled trials

Systemic and local effects following intra-articular injection of FX006, an extended release, PLGA microsphere formulation of triamcinolone acetonide: results from two nonclinical toxicity studies in dogs

Synovial and systemic pharmacokinetics of triamcinolone acetonide following intra-articular injection of an extended release formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis

A single intra-articular dose of Fx006, an extended-release formulation of triamcinolone acetonide, has a similar effect on cartilage in healthy dogs as the commonly used kenalog-40® suspension

Sustained and profound analgesic benefits in people with osteoarthritis of the knee using FX006, an intra-articular extended-release formulation of triamcinolone acetonide: Results from a double-blind, randomized, parallel-group, dose-ranging study

Sustained efficacy of intra-articular FX006 in a rat model of osteoarthritis

Prolonged joint residency of triamcinolone acetonide after an intra-articular injection of FX006, a sustained release formulation for the treatment of osteoarthritis

FX006 prolongs the residency of triamcinolone acetonide in the synovial tissues of patients with knee osteoarthritis

Safety and efficacy of FX006 in patients with osteoarthritis of the knee

A novel structural status assessment of oa is strongly associated with all patient important outcomes - an mri study of 9,433 knees from the osteoarthritis initiative

The rat homolog to FX201, a gene therapy in development for the treatment of osteoarthritis, demonstrates dose-dependent decreases in the severity of cartilage and bone lesions following anterior cruciate ligament transection

Dose-dependent chondroprotective effects of triamcinolone acetonide on inflamed and injured cartilage using an in vitro model

The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease

(262) - Assay sensitivity of average daily pain (ADP) and western ontario and mcmaster osteoarthritis index A-pain (WOMAC-A) in a phase 3 trial of intra-articular FX006 for osteoarthritis knee pain

Efficacy of xanomeline in Alzheimer disease : Cognitive improvement measured using the computerized neuropsychological test battery (CNTB)

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines

Growing Optic Nerve Fibers Follow Neighbors during Embryogenesis

Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist

557 The MI-selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of patients with mild to moderate Alzheimer's disease

The M1 muscarinic agonist xanomeline improves both cognitive and behavioral deficits in Alzheimer's disease

Quality-of-life assessment in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines

Effects of Central Muscarinic-1 Receptor Stimulation on Blood Pressure Regulation

Suchergebnisse filtern